Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

First time unlucky for Australian listing of Pharmaxis' cystic fibrosis drug

This article was originally published in Scrip

Executive Summary

Pharmaxis' first attempt at getting its cystic fibrosis therapy Bronchitol (mannitol) included in Australia's reimbursement scheme has been unsuccessful, although the company remains confident it will be eventually be covered.



Related Companies